Supply of EpiPen and EpiPen Junior

18th December 2018

You may be aware of the recent DHSC Supply Disruption Alert on EpiPen Junior adrenaline auto-injectors (AAIS) which advised conserving supplies for patients who truly need them.

Previous guidance implemented controls on the supply of 150microgram adrenaline auto-injectors. Stock positions are now sufficient to allow further relaxation of the prescription validation protocol for Jext and Emerade paediatric devices, whilst prescription validation will still be required for EpiPen Junior devices.

Pharmacies will now be able to order stock of adrenaline auto-injectors in the same way as they did prior to the implementation of the prescription validation process. The wholesalers will have caps on the amount of stock which can be ordered, but this is in line with processes in place previously. Pharmacies are advised to speak to wholesalers directly if further information about current caps is required.

EpiPen Junior will remain on a wholesaler prescription management process, this allows pharmacies to order up to a maximum of two EpiPen Junior devices per prescription. Pharmacies are required to send anonymised prescriptions to Alliance Healthcare’s prescription validation service either by fax or by email

Further information can be found on the EpiPen website, under instructions for pharmacists, this can be found at the following link: http://www.epipen.co.uk

Thank you for all your help during this supply issue and for managing stocks of adrenaline auto-injectors closely. We do urge pharmacies to continue to order sensibly during this time. Stocks will be closely monitored over the coming weeks to ensure adequate supplies are available to order.